First Diagnostic Radiotracer for Early Diagnosis of Alzheimer’s Disease Approved in Canada
ISOLOGIC has received marketing authorization from Health Canada for the commercial production and market supply of NeuraCeq in Canada. NeuraCeq is the first diagnostic radiotracer to support the early diagnosis of Alzheimer’s disease (AD) that is commercially available in the country. NeuraCeq availability in Canada was previously limited to investigational medicine purposes.
“The commercial availability of NeuraCeq will provide physicians throughout Canada a non-invasive method to more confidently and accurately assess complex and atypical cases of cognitively impaired patients for early diagnosis of Alzheimer’s disease,” said Doctor Jean-Paul Soucy, Medical Director of PET imaging at the Montreal Neurological Institute. “In the absence of an approved disease modifying treatment, advancing our ability to make an early and accurate AD diagnosis is critically important to providing optimal symptomatic treatment and non-pharmacological measures to manage disease progression and quality of life in these patients.”
The Polluted Brain
There is mounting evidence that polluted air can lead to dementia!
Read the complete article in Science magazine.
A team from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and Boston University, is in the process of creating a feedback system that lets people correct robot mistakes instantly with their brains.
Identifying the Neural Signature of Healthy Brain Aging
A new study reports the ability to modulate brain activity when it comes to shutting off processes irrelevant to a task may be compromised in older people.
Read the complete article in Neuroscience News.
Autism Diagnosis by Brain Scan?
Recent reports that it might be possible to use MRI to identify at-risk children are exciting, but we are still a long way from autism diagnosis by brain scan.